TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction

TScan Therapeutics Inc. (NASDAQ: TCRX ) on Wednesday announced a major corporate reorganization to prioritize its in vivo solid tumor pipeline, prompting a workforce reduction of approximately 75%. The clinical-stage biotechnology company is shifting capital toward its lead oncology programs while pausing new enrollment in its Phase 3 ALLOHA-2 study for hematologic malignancies due to funding constraints . Advancing In Vivo Solid Tumor Therapies The strategic pivot focuses TScan’s efforts on developing in vivo-engineered TCR-T therapies, starting as singleplexed treatments and ultimately expanding into multiplexed options . The company advanced two product candidates targeting PRAME and MAGE-A4 into IND-enabling studies. By leveraging an in vivo engineering method, TScan aims to bypass ...